Claritas HealthTech has announced the completion of iPETcertum, a new software device designed to automate the detection, delineation, and quantification of isotope uptake in PET scans.

The software device extends the capabilities of the existing Claritas iPET, a software as a medical device (SaMD) that helps in accelerating scan times and reducing contrast doses in PET, PET-CT/MRI scans while maintaining diagnostic image quality.

iPETcertum offers clinicians the additional capability to automatically locate lesions with specified values, providing accurate quantification of isotope uptake in tissues and organs through standard uptake values (SUV), SUVmax, and volume measurements.

Claritas said that the Claritas iPET, which already obtained US Food and Drug Administration (FDA) 510k clearance, is commercially available.

The company anticipates its iPETcertum software device to receive FDA 510k clearance by the fourth quarter of this year.

Claritas co-founder and director Chetan Baxi said: “The completion of iPETcertum marks a significant milestone of our R&D with our clinical partners.

“This software augments the clinician’s workflow and enables faster and more accurate reporting. This in turn allows the doctors to focus more of their time on patient care."

The combined functionalities of Claritas iPET and iPETcertum are planned to be showcased at the upcoming SNMMI Annual Meeting in June 2024 in Toronto, Canada.

Last year, Claritas HealthTech partnered with PwC for the deployment of the former’s medical imaging platforms.

Through the partnership, the companies will jointly work to roll out, install and support medical image enhancement and AI diagnostic software products suite.